Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets
DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ — Brii Biosciences Limited ('Brii Bio,' stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ('Joincare Group'). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region.
Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales.
BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.
Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: 'The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections.'
Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, 'The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs.
We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options.'
About BRII-693
BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693.
About Brii Bio
Brii Biosciences Limited ('Brii Bio', stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.
About Joincare Group
Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development.
Forward-looking Statements
This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 hours ago
- The Star
Cambodia sees 25% rise in Chinese tourist arrivals to Unesco-listed Angkor in first half of 2025
Almost 568,000 foreigners from 171 countries and regions toured the ancient park in the first half of this year, generating a gross revenue of US$26.3 million from ticket sales. - Allphoto Bangkok/Unsplash PHNOM PENH: Cambodia has seen a remarkable increase in the number of Chinese tourists to its iconic Angkor Archaeological Park in the first half of 2025, an official report said on Thursday (July 3). A total of 47,571 Chinese tourists visited the Unesco-listed world heritage site during the January-June period, up 25 per cent over the same period last year, said the state-owned Angkor Enterprise's report. China remained the fourth biggest source of international tourist arrivals to Angkor after the United States, the United Kingdom and France, it added. According to the report, a total of 567,673 foreigners from 171 countries and regions toured the ancient park in the first half of this year, generating a gross revenue of US$26.3 million from ticket sales. Thong Mengdavid, a lecturer at the Institute for International Studies and Public Policy of the Royal University of Phnom Penh, said that with 2025 being designated as the Cambodia-China Tourism Year, a significant surge in Chinese tourist arrivals to the Angkor Archaeological Park is predicted. "This increase will likely be driven by enhanced bilateral cooperation, promotional campaigns and greater accessibility through direct flights and group tour packages," he told Xinhua. Located in the northwest Siem Reap province, the 401-square-km Angkor Archaeological Park, the kingdom's most popular tourist destination, is home to 91 ancient temples, built from the ninth to the 13th centuries. - Xinhua
Borneo Post
2 hours ago
- Borneo Post
Sibu still best town outside Greater China in preserving Chinese culture, says Tiang
(From seventh left) Ting, Chieng, Tiang, Lau and others participating in the ribbon cutting to launch the Food Festival and Cultural Street at the BCF on Friday. SIBU (July 4): Sibu remains the most comprehensive and complete guardian of Chinese culture outside of China, Hong Kong, and Taiwan, said Sarawak Deputy Minister for Public Health, Housing and Local Government, Datuk Michael Tiang. He praised the unity among the town's Chinese community, noting that people from different dialect groups celebrate together with openness, inclusiveness, and mutual respect. 'They are continuing our cultural legacy, rejecting extreme racism, and working hand-in-hand and heart-to-heart to accelerate the Sarawak government's development policies for ethnic unity that has become a unique attraction,' he said during the launch of the Food Festival and Cultural Street, held in conjunction with the Borneo Cultural Festival (BCF) 2025 at the Sibu Town Square last night. Also present were Bukit Assek assemblyman Joseph Chieng, Sibu Municipal Council chairman Clarence Ting and United Chinese Association (UCA) president Lau Ing Siong. Tiang said the Chinese community must take collective responsibility for preserving their ancestral folk culture, which he described as deeply rooted and irreplaceable by modern technology. He emphasised the need to uphold and promote the community's history and heritage, highlighting that the century-old legacy of the Chinese in Sibu offers a rich and memorable cultural experience. He expressed hope that the event would further strengthen community bonds and contribute to a vibrant, dignified celebration of culture, helping to realise Sibu's vision of prosperity. Tiang also noted that the BCF, now in its 22nd year since it began in 2003, continues to grow in prominence. 'Every year, the number of visitors and group performances bring new highlights to both locals and international tourists, not only boosting Sibu's cultural branding but also showcasing the rich diversity of Sibu and Sarawak – in ethnicity, culture, and religion – a core value Sibu residents are proud of,' he said. He called on leaders of various associations to use the festival to highlight their dialect groups' unique cuisines, with English translations provided where possible to aid international visitors. 'I believe only by branding and packaging our cuisine well can we preserve its cultural value and uniqueness,' he said. Although the BCF spans just 10 days, Tiang expressed confidence that it would offer an engaging and authentic Chinese cultural experience. BCF 2025 Chinese culture Michael Tiang Sibu
The Sun
3 hours ago
- The Sun
French spirits shares stabilise as China duties may not apply to all
SHARES of French spirits makers regained some ground on Friday after falling in early trading, as China spared major cognac producers from new duties on EU brandy, provided they sell at a minimum price. Pernod Ricard's shares were down 0.5% while Remy Cointreau was 0.3% lower by 1130 GMT, after falling as much as 4.4% and 6.8% respectively earlier in the session. LVMH , owner of Hennessy, fell 1.4%. China's ruling is good news for the French cognac industry because it means there will be no anti-dumping duties for all those companies that stick to their minimum import price commitments, three industry sources told Reuters. Remy Cointreau and Pernod Ricard said in statements on Friday that they had agreed with Chinese authorities on a minimum import price to avoid duties. Both companies said the agreement did not constitute an acknowledgment of dumping practices. China will impose duties of up to 34.9% to brandy companies exporting from the EU and not respecting the price commitments for a period of five years starting from Saturday. The ruling follows an investigation into European brandy, most of it cognac from France. - Reuters
